



Multi-Faceted Epigenetic Dysregulation in Acute Myeloid Leukemia

Guest Editors:

Dr. Shuchi Agrawal-Singh

Wellcome Trust—Medical
Research Council Cambridge
Stem Cell Institute, University of
Cambridge, Cambridge CB2 1TN,
UK

Dr. Stefanie Göllner

Department of Medicine V-
Hematology, Oncology and
Rheumatology, University
Hospital Heidelberg, Im
Neuenheimer Feld 410, 69120
Heidelberg, Germany

Deadline for manuscript
submissions:

23 August 2024

Message from the Guest Editors

AML is a complex heterogenous disease characterized by the presence of highly proliferative myeloid progenitor cells with reduced capacity to differentiate. Recent advanced understanding combining knowledge about recurring genetic mutations and epigenetic alterations suggests that AML is an epigenetic disease, mainly because the disease is driven by driving/recurring mutations in epigenetic modulators, DNA/chromatin modifiers, RNA splicing, 3D chromosomal interactions, and chromatin remodeling complexes SWI/SNF and NPM1. Many of these regulatory processes consist of multiple enzymes and are probably interconnected. Moreover, the role of IDR (intrinsically disordered region) in oncoproteins such as NUP98-HOXA9 or UTX to form liquid condensate that controls transcription and genome architecture has provided new insights for epigenetic understanding in AML.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: chromatin regulation, nuclear topology and 3D chromatin architecture, liquid condensates and phase separation, epi-mechanisms, RNA modifications, epi-metabolism.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)